Previous Article | Next Article 
Journal of Virology, June 2007, p. 6548-6562, Vol. 81, No. 12
0022-538X/07/$08.00+0 doi:10.1128/JVI.02749-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors
Amandeep K. Dhillon,1,
Helen Donners,1,2,
Ralph Pantophlet,1
Welkin E. Johnson,3
Julie M. Decker,5
George M. Shaw,5
Fang-Hua Lee,6
Douglas D. Richman,4
Robert W. Doms,6
Guido Vanham,2 and
Dennis R. Burton1*
Department of Immunology, The Scripps Research Institute, La Jolla, California 92037,1
Department of Microbiology, Institute of Tropical Medicine, B-2000, Antwerp, Belgium,2
New England Primate Research Center, Harvard Medical School, Southborough, Massachusetts 01722,3
Center for AIDS Research, University of California, San Diego, California 92093-0679, and VA San Diego Healthcare System, La Jolla, California 92161,4
Department of Medicine and Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, 35294,5
Department of Microbiology, University of Pennsylvania, Philadelphia, Pennsylvania 191046
Received 13 December 2006/
Accepted 25 March 2007
Attempts to elicit broadly neutralizing antibody responses by human immunodeficiency virus type 1 (HIV-1) vaccine antigens have been met with limited success. To better understand the requirements for cross-neutralization of HIV-1, we have characterized the neutralizing antibody specificities present in the sera of three asymptomatic individuals exhibiting broad neutralization. Two individuals were infected with clade B viruses and the third with a clade A virus. The broadly neutralizing activity could be exclusively assigned to the protein A-reactive immunoglobulin G (IgG) fraction of all three donor sera. Neutralization inhibition assays performed with a panel of linear peptides corresponding to the third hypervariable (V3) loop of gp120 failed to inhibit serum neutralization of a panel of HIV-1 viruses. The sera also failed to neutralize chimeric simian immunodeficiency virus (SIV) and HIV-2 viruses displaying highly conserved gp41-neutralizing epitopes, suggesting that antibodies directed against these epitopes likely do not account for the broad neutralizing activity observed. Polyclonal IgG was fractionated on recombinant monomeric clade B gp120, and the neutralization capacities of the gp120-depleted samples were compared to that of the original polyclonal IgG. We found that the gp120-binding antibody population mediated neutralization of some isolates, but not all. Overall, the data suggest that broad neutralization results from more than one specificity in the sera but that the number of these specificities is likely small. The most likely epitope recognized by the monomeric gp120 binding neutralizing fraction is the CD4 binding site, although other epitopes, such as the glycan shield, cannot be excluded.
* Corresponding author. Mailing address: The Scripps Research Institute, Department of Immunology (IMM-2), 10550 North Torrey Pines Road, La Jolla, CA 92037. Phone: (858) 784-9298. Fax: (858) 784-8360. E-mail:
burton{at}scripps.edu
Published ahead of print on 4 April 2007.
These authors contributed equally to this work.
Journal of Virology, June 2007, p. 6548-6562, Vol. 81, No. 12
0022-538X/07/$08.00+0 doi:10.1128/JVI.02749-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Wu, X., Zhou, T., O'Dell, S., Wyatt, R. T., Kwong, P. D., Mascola, J. R.
(2009). Mechanism of Human Immunodeficiency Virus Type 1 Resistance to Monoclonal Antibody b12 That Effectively Targets the Site of CD4 Attachment. J. Virol.
83: 10892-10907
[Abstract]
[Full Text]
-
Gray, E. S., Taylor, N., Wycuff, D., Moore, P. L., Tomaras, G. D., Wibmer, C. K., Puren, A., DeCamp, A., Gilbert, P. B., Wood, B., Montefiori, D. C., Binley, J. M., Shaw, G. M., Haynes, B. F., Mascola, J. R., Morris, L.
(2009). Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors. J. Virol.
83: 8925-8937
[Abstract]
[Full Text]
-
Dosenovic, P., Chakrabarti, B., Soldemo, M., Douagi, I., Forsell, M. N. E., Li, Y., Phogat, A., Paulie, S., Hoxie, J., Wyatt, R. T., Karlsson Hedestam, G. B.
(2009). Selective Expansion of HIV-1 Envelope Glycoprotein-Specific B Cell Subsets Recognizing Distinct Structural Elements Following Immunization. J. Immunol.
183: 3373-3382
[Abstract]
[Full Text]
-
O'Rourke, S. M., Schweighardt, B., Scott, W. G., Wrin, T., Fonseca, D. P. A. J., Sinangil, F., Berman, P. W.
(2009). Novel Ring Structure in the gp41 Trimer of Human Immunodeficiency Virus Type 1 That Modulates Sensitivity and Resistance to Broadly Neutralizing Antibodies. J. Virol.
83: 7728-7738
[Abstract]
[Full Text]
-
Shen, X., Parks, R. J., Montefiori, D. C., Kirchherr, J. L., Keele, B. F., Decker, J. M., Blattner, W. A., Gao, F., Weinhold, K. J., Hicks, C. B., Greenberg, M. L., Hahn, B. H., Shaw, G. M., Haynes, B. F., Tomaras, G. D.
(2009). In Vivo gp41 Antibodies Targeting the 2F5 Monoclonal Antibody Epitope Mediate Human Immunodeficiency Virus Type 1 Neutralization Breadth. J. Virol.
83: 3617-3625
[Abstract]
[Full Text]
-
Guan, Y., Sajadi, M. M., Kamin-Lewis, R., Fouts, T. R., Dimitrov, A., Zhang, Z., Redfield, R. R., DeVico, A. L., Gallo, R. C., Lewis, G. K.
(2009). Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc. Natl. Acad. Sci. USA
106: 3952-3957
[Abstract]
[Full Text]
-
Davis, K. L., Bibollet-Ruche, F., Li, H., Decker, J. M., Kutsch, O., Morris, L., Salomon, A., Pinter, A., Hoxie, J. A., Hahn, B. H., Kwong, P. D., Shaw, G. M.
(2009). Human Immunodeficiency Virus Type 2 (HIV-2)/HIV-1 Envelope Chimeras Detect High Titers of Broadly Reactive HIV-1 V3-Specific Antibodies in Human Plasma. J. Virol.
83: 1240-1259
[Abstract]
[Full Text]
-
Sather, D. N., Armann, J., Ching, L. K., Mavrantoni, A., Sellhorn, G., Caldwell, Z., Yu, X., Wood, B., Self, S., Kalams, S., Stamatatos, L.
(2009). Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection. J. Virol.
83: 757-769
[Abstract]
[Full Text]
-
Li, Y., Svehla, K., Louder, M. K., Wycuff, D., Phogat, S., Tang, M., Migueles, S. A., Wu, X., Phogat, A., Shaw, G. M., Connors, M., Hoxie, J., Mascola, J. R., Wyatt, R.
(2009). Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals. J. Virol.
83: 1045-1059
[Abstract]
[Full Text]
-
Blish, C. A., Dogan, O. C., Derby, N. R., Nguyen, M.-A., Chohan, B., Richardson, B. A., Overbaugh, J.
(2008). Human Immunodeficiency Virus Type 1 Superinfection Occurs despite Relatively Robust Neutralizing Antibody Responses. J. Virol.
82: 12094-12103
[Abstract]
[Full Text]
-
Binley, J. M., Lybarger, E. A., Crooks, E. T., Seaman, M. S., Gray, E., Davis, K. L., Decker, J. M., Wycuff, D., Harris, L., Hawkins, N., Wood, B., Nathe, C., Richman, D., Tomaras, G. D., Bibollet-Ruche, F., Robinson, J. E., Morris, L., Shaw, G. M., Montefiori, D. C., Mascola, J. R.
(2008). Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C. J. Virol.
82: 11651-11668
[Abstract]
[Full Text]
-
Ferraz, R. M., Martinez, M. A., Cubarsi, R., Villaverde, A.
(2008). Antiretroviral Therapy-Induced Functional Modification of IgG4 and IgM Responses in HIV-1-Infected Individuals Screened by an Allosteric Biosensor. J Biomol Screen
13: 817-821
[Abstract]
-
Vaine, M., Wang, S., Crooks, E. T., Jiang, P., Montefiori, D. C., Binley, J., Lu, S.
(2008). Improved Induction of Antibodies against Key Neutralizing Epitopes by Human Immunodeficiency Virus Type 1 gp120 DNA Prime-Protein Boost Vaccination Compared to gp120 Protein-Only Vaccination. J. Virol.
82: 7369-7378
[Abstract]
[Full Text]
-
Montero, M., van Houten, N. E., Wang, X., Scott, J. K.
(2008). The Membrane-Proximal External Region of the Human Immunodeficiency Virus Type 1 Envelope: Dominant Site of Antibody Neutralization and Target for Vaccine Design. Microbiol. Mol. Biol. Rev.
72: 54-84
[Abstract]
[Full Text]
-
Li, Y., Cleveland, B., Klots, I., Travis, B., Richardson, B. A., Anderson, D., Montefiori, D., Polacino, P., Hu, S.-L.
(2008). Removal of a Single N-Linked Glycan in Human Immunodeficiency Virus Type 1 gp120 Results in an Enhanced Ability To Induce Neutralizing Antibody Responses. J. Virol.
82: 638-651
[Abstract]
[Full Text]
-
Gray, E. S., Moore, P. L., Pantophlet, R. A., Morris, L.
(2007). N-Linked Glycan Modifications in gp120 of Human Immunodeficiency Virus Type 1 Subtype C Render Partial Sensitivity to 2G12 Antibody Neutralization. J. Virol.
81: 10769-10776
[Abstract]
[Full Text]